Clinical Trial Update: Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis) [NA]

View source ↗

Summary

A completed clinical trial evaluated 0.5 mg intraocular ranibizumab (Lucentis) for diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University of Luebeck | Conditions: Age-Related Macular Degeneration | NA | Status: COMPLETED